Brief: Ani Pharmaceuticals Announces Results From New Day Clinical Trial Of Iluvien® For Use In Patients With Diabetic Macular Edema (Dme)

ANI Pharmaceuticals

23/07/2025 11:54

July 23 (Reuters) - ANI Pharmaceuticals Inc ANIP.O:

ANI PHARMACEUTICALS ANNOUNCES RESULTS FROM NEW DAY CLINICAL TRIAL OF ILUVIEN® FOR USE IN PATIENTS WITH DIABETIC MACULAR EDEMA (DME)

ANI PHARMACEUTICALS INC - PRIMARY ENDPOINT WAS MEAN NUMBER OF SUPPLEMENTAL AFLIBERCEPT INJECTIONS

ANI PHARMACEUTICALS INC - ILUVIEN SHOWED NUMERICAL REDUCTION IN INJECTIONS BUT NOT SIGNIFICANT

ANI PHARMACEUTICALS INC - SECONDARY ENDPOINT MET WITH MEAN TIME OF 185.4 DAYS IN ILUVIEN ARM

ANI PHARMACEUTICALS INC - ILUVIEN WELL TOLERATED WITH CONSISTENT SAFETY PROFILE IN TRIAL

Source text: ID:nGNX7cSqJ3

Further company coverage: ANIP.O

 ((Reuters.Briefs@thomsonreuters.com;))